Novartis AG ADR
$ 167.11
1.46%
24 Feb - close price
- Market Cap 318,376,673,000 USD
- Current Price $ 167.11
- High / Low $ 167.84 / 166.10
- Stock P/E 23.04
- Book Value 24.18
- EPS 7.15
- Next Earning Report 2026-04-28
- Dividend Per Share $4.67
- Dividend Yield 2.9 %
- Next Dividend Date 2026-03-16
- ROA 0.11 %
- ROE 0.31 %
- 52 Week High 167.86
- 52 Week Low 97.72
About
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Analyst Target Price
$140.30
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-30 | 2024-10-28 | 2024-07-17 | 2024-04-22 | 2024-01-30 | 2023-10-24 | 2023-07-17 | 2023-04-25 |
| Reported EPS | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 | 1.83 | 1.71 |
| Estimated EPS | 2 | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 | 1.76 | 1.53 |
| Surprise | 0.03 | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 | 0.07 | 0.18 |
| Surprise Percentage | 1.5% | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% | 3.9773% | 11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.99 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-16 | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None |
| Amount | $4.772961 | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 |
Next Dividend Records
| Dividend per share (year): | $4.67 |
| Dividend Yield | 2.9% |
| Next Dividend Date | 2026-03-16 |
| Ex-Dividend Date | 2026-03-11 |
Recent News: NVS
2026-02-24 12:51:37
Novartis announced new real-world data showing that Pluvicto™ is effective when used earlier in the treatment of metastatic castration-resistant prostate cancer (mCRPC), specifically before chemotherapy. The data indicates a longer median progression-free survival (PFS) in chemo-naïve patients who received Pluvicto after only one androgen receptor pathway inhibitor (ARPI), consistent with prior clinical trial results. Furthermore, a separate analysis highlighted a significant opportunity to improve adherence to guideline-recommended treatment in metastatic hormone-sensitive prostate cancer by increasing combination therapy usage.
2026-02-24 01:38:00
Novartis has confidentially settled a lawsuit brought by the estate of Henrietta Lacks, which accused the drugmaker of profiting from her "immortal" cells without consent. This settlement is a significant development in the Lacks family's ongoing legal campaign against pharmaceutical companies that have utilized the HeLa cell line. While Novartis's case is closed, similar lawsuits against Ultragenyx Pharmaceutical and Viatris continue, with the Lacks family's lawyers indicating more litigation is likely forthcoming.
2026-02-24 00:51:37
Novartis India shares surged 20% following an open offer initiated by private equity firm ChrysCapital and two other investment firms after its parent company, Novartis AG, decided to divest its 70.69% stake. The decision to exit the Indian subsidiary is part of Novartis AG's global strategy to focus on its core innovative medicines business. The open offer is priced at ₹1,000 per share, significantly below the current market price, raising questions about potential revisions or opportunities for retail investors.
2026-02-23 06:08:48
Novartis presented data on its drug Rhapsido(R) (remibrutinib) at the AAAAI conference, indicating its potential for use in conditions beyond chronic spontaneous urticaria (CSU). The announcement, made on February 23, 2026, highlights new findings for the drug. This news follows other recent developments for Novartis, including analyst ratings, divestment plans for its Indian arm, and comments from its CEO regarding US healthcare rhetoric.
2026-02-23 01:01:37
Novartis announced that the FDA has approved an expanded indication for Entresto (sacubitril/valsartan) to reduce cardiovascular death and hospitalization in adult patients with chronic heart failure, including those with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). This approval significantly broadens the patient population eligible for treatment, particularly benefiting those with left ventricular ejection fraction (LVEF) below normal. The expanded label is based on the PARAGON-HF study and empowers healthcare professionals to offer Entresto to a wider range of chronic heart failure patients who previously had limited approved treatment options.
2026-02-22 22:33:21
Novartis announced it will present new data from its oncology and hematology portfolio at the 2021 ASCO Annual Meeting and EHA Virtual Congress. Key presentations will include overall survival data for investigational radioligand therapy 177 Lu-PSMA-617 in metastatic prostate cancer and Kisqali (ribociclib) in breast cancer. The company will also share results on iptacopan for paroxysmal nocturnal hemoglobinuria, updated efficacy for Kymriah in follicular lymphoma, and various other promising therapies across its four therapeutic platforms.
